Exosome Delivery Vehicle Energy Enhancement
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical delivery vehicles, such as extracellular vesicles and exosomes, face challenges in efficiently being taken up by target cells, limiting their effectiveness in drug delivery due to energy-dependent uptake mechanisms and the presence of endogenous nucleic acids that can be harmful.
Innovation Solution
An enhanced delivery vehicle is developed, comprising a base delivery vehicle, such as exosomes, loaded with energy-rich substances like ATP or agents that increase energy-rich substance production in target cells, along with additional cargo, to enhance uptake and minimize harmful nucleic acid content.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If exosomes are used for drug delivery, then they can efficiently deliver cargo to target cells, but their uptake by target cells is limited due to energy-dependent mechanisms
Solution Approach 1:
The patent applies preliminary action by pre-loading exosomes with energy-rich substances (ATP, GTP, CTP, UTP) before administration. This preliminary energization of the delivery vehicle ensures that when the exosome reaches the target cell, sufficient energy is available to drive the energy-dependent uptake process, thereby resolving the contradiction between cargo delivery efficiency and uptake reliability
Solution Approach 2:
The patent changes the energy state parameter of the exosome by incorporating energy-rich substances. This parameter change from a standard exosome to an energy-enhanced exosome directly addresses the energy-dependent uptake limitation, improving both the reliability of uptake and the overall productivity of cargo delivery
2Adaptability or versatility
If exosomes are used for delivery, then they can mediate cellular communication, but endogenous nucleic acids in exosomes can be harmful
Solution Approach 1:
The patent applies the extraction principle by removing endogenous nucleic acids from exosomes through purification steps while retaining the exosome structure and cellular communication capabilities. This selective removal eliminates harmful factors (nucleic acids) while preserving the beneficial functions (cargo delivery and cellular communication), thus resolving the contradiction between adaptability and harmful factors
Solution Approach 2:
The patent applies local quality by creating exosomes with non-uniform composition - the exosome membrane and protein cargo are retained for beneficial functions, while endogenous nucleic acids are removed to eliminate harm. This localized modification of exosome composition allows the system to simultaneously achieve versatility in cellular communication and elimination of harmful factors
3Reliability
If uptake of exosomes is increased through energy-dependent processes, then target cell uptake improves, but the complexity of the delivery system increases
Solution Approach 1:
The patent applies self-service by enabling the exosome to self-energize through pre-loaded energy-rich substances. The exosome carries its own energy supply (ATP, GTP, CTP, or UTP) internally, eliminating the need for external energy supplementation or complex delivery system modifications. This self-contained approach improves target cell uptake reliability while minimizing increases in overall system complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The enhanced delivery vehicle achieves a significant increase in target cell uptake, demonstrated by over 300% increase in ATP-loaded exosomes, while ensuring safety by minimizing endogenous nucleic acids, thereby improving therapeutic cargo delivery.
Implementation Method 1
Experimental evidence suggests that EV/exosome uptake is accomplished via endocytosis in the majority of cases
Implementation Method 2
The capacity of cells to take up exosomes is greatly attenuated at 4° C., suggesting an energy-dependent non-passive process
Data Source
AI summary
An enhanced delivery vehicle for a treating agent includes a base delivery vehicle, which is adapted for carrying a treating agent for uptake thereof by a target cell, and an enhancing component. The enhancing component may be at least one energy rich substance, at least one agent which increases production of at least one energy rich substance in the target cell, or a combination thereof. The enhancing component enhances the uptake of the base delivery vehicle by the target cell. Non-limiting examples of the base delivery vehicle include exosomes, microvesicles, apoptotic bodies, oncosomes, extracellular vesicles, microparticles, liposomes, and nanoparticles. In one embodiment, the enhancing component is an exosome engineered to be substantially devoid of endogenous nucleic acids. In one embodiment, the enhancing component is at least one energy rich substance including, but not limited to, ATP, NADH, NADPH, FADH2, acetyl CoA, glucose, pyruvate, GTP, CTP, and UTP.